AI-generated summary
The authors report a prospective clinical study of 47 patients with chemotherapy-induced peripheral neuropathy in the lower limbs who received photobiomodulation twice weekly for two weeks. Sensory symptom questionnaires improved, and balance and gait speed measures improved on rigid surfaces, while the authors describe PBM as a promising low-cost option. The study had no control group described in the abstract.
- Participants
- 47
- Who or what was studied
- Patients with chemotherapy-induced peripheral neuropathy in the lower limbs
- Wavelengths
- 630, 850 nm
- Limits stated in the abstract
- The abstract describes a single-group prospective study without a stated control group, so the findings cannot be attributed to PBM alone.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Neuropathy, Oxidative stress, Near-infrared, Inflammation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.